To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.
Themis Bioscience and the Institut Pasteur have good news to report from a Phase I trial of their Chikungunya fever vaccine candidate. And the pair thinks its successful results just might lead to advances in other diseases, too.
As Pfizer's Trumenba rolls out in the U.S., it may get a head start on Novartis' Bexsero, which is still awaiting FDA approval. But the drug giant still doesn't yet have what it needs to build a considerable lead: a recommendation from the CDC's Advisory Committee on Immunization Practices.
An HIV vaccine regimen that failed in a notable clinical trial conducted in Thailand has been given a new chance to prove itself.
With several companies now expediting Ebola vaccines in an attempt to halt the spread of the deadly virus, Novavax has jumped in the race, announcing that it's using its nanoparticle vaccine technology to advance a candidate of its own.
As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.
What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.
A new study suggests that a tuberculosis vaccine with low efficacy in adolescents and adults could be more successful at reducing rates of the disease than a vaccine intended for infants.
Hoping to boost its chances of FDA approval early next year, Pfizer has unveiled results from a Phase II clinical trial for its meningitis B vaccine, showing that the jab is safe and effective in adolescents when given alongside a licensed vaccine for human papillomavirus.
As the Ebola outbreak continues to ravage Liberia, Guinea and Sierra Leone, GlaxoSmithKline said Phase I trials of its experimental Ebola vaccine are expected to start in West Africa in the next few weeks, and Phase II trials are likely to begin in early 2015.